[
    [
        {
            "time": "2019-07-31",
            "original_text": "有34家公司获重要股东增减持，延安必康已被连续减持89次，减持股份。",
            "features": {
                "keywords": [
                    "增减持",
                    "延安必康",
                    "连续减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "有34家公司获重要股东增减持，延安必康已被连续减持89次，减持股份。",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "暴风冯鑫行贿非国家工作人员被拘。",
            "features": {
                "keywords": [
                    "暴风",
                    "冯鑫",
                    "行贿",
                    "被拘"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "暴风冯鑫行贿非国家工作人员被拘。",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "第二轮科创板打新本周开启，平均市盈率高于第一批。",
            "features": {
                "keywords": [
                    "科创板",
                    "打新",
                    "市盈率"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "第二轮科创板打新本周开启，平均市盈率高于第一批。",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "K药上半年收入逼近50亿美元，福建药招新动向。",
            "features": {
                "keywords": [
                    "K药",
                    "收入",
                    "福建药招"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "K药上半年收入逼近50亿美元，福建药招新动向。",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "北上资金净卖出贵州茅台2.34亿、五粮液1.8亿元。",
            "features": {
                "keywords": [
                    "北上资金",
                    "贵州茅台",
                    "五粮液",
                    "净卖出"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "北上资金净卖出贵州茅台2.34亿、五粮液1.8亿元。",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "恒瑞医药：SHR-1316注射液获得临床试验通知书。",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "临床试验",
                    "通知书"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：SHR-1316注射液获得临床试验通知书。",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "19家药企入选国家技术创新示范企业。",
            "features": {
                "keywords": [
                    "药企",
                    "技术创新",
                    "示范企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "19家药企入选国家技术创新示范企业。",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "中药保护申请16项证明事项取消，荐5股。",
            "features": {
                "keywords": [
                    "中药",
                    "保护申请",
                    "取消",
                    "荐股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中药保护申请16项证明事项取消，荐5股。",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "医药产业迎来发展大变革，药企纷纷走上创新之路。",
            "features": {
                "keywords": [
                    "医药产业",
                    "发展变革",
                    "创新"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药产业迎来发展大变革，药企纷纷走上创新之路。",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-31",
            "original_text": "辉瑞剥离伟哥等明星药物，专注创新药应对变化市场。",
            "features": {
                "keywords": [
                    "辉瑞",
                    "剥离",
                    "伟哥",
                    "创新药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "辉瑞剥离伟哥等明星药物，专注创新药应对变化市场。",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]